In MGMT methylated glioblastoma, when compared to >5 cm3 residual CE tumor (224 days; 95% CI 164–284), we observed a significantly longer median overall survival for a residual CE tumor volume of 1–5 cm3 (470 days; 95% CI 330–610; p < 0.0001) and 0–1 cm3 (536 days; 95% CI 319–752; p = 0.003) (Figure 1C). The gene discussed is MGMT; the disease is neoplasm.